Comparison of low-dose higher-relaxivity and standard-dose lower-relaxivity contrast media for delayed-enhancement mri: A blinded randomized crossover study

Benjamin Y.C. Cheong, Cihan Duran, Ourania A. Preventza, Raja Muthupillai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE. The gadolinium-based MRI contrast agent gadobenate dimeglumine has nearly twice the MR relaxivity of gadopentetate dimeglumine at 1.5 T. The purpose of this study was to determine whether a lower dose (0.1 mmol/kg) of gadobenate dimeglumine can be used to obtain delayed-enhancement MR images comparable to those obtained with a standard dose (0.2 mmol/kg) of gadopentetate dimeglumine. SUBJECTS AND METHODS. In this blinded randomized crossover study, 20 patients with known myocardial infarction underwent two separate delayed-enhancement MRI examinations after receiving 0.1 mmol/kg gadobenate dimeglumine and 0.2 mmol/kg gadopentetate dimeglumine (random administration). The conspicuity of lesion enhancement 5, 10, and 20 minutes after contrast administration was quantified as relative enhancement ratio (RER). RESULTS. With either gadolinium-based contrast agent, damaged myocardium had higher signal intensity than normal remote myocardium (RER > 4) on delayed-enhancement MR images, and the blood RER declined over time after contrast administration. The blood RER was not significantly higher for gadobenate dimeglumine than for gadopentetate dimeglumine at 5 and 10 minutes. Nevertheless, there was a larger reduction in blood RER for gadobenate dimeglumine than for gadopentetate dimeglumine between 5 and 10 minutes and between 10 and 20 minutes. The volumes of enhancement were similar for gadobenate dimeglumine (13.6 ± 8.8 cm3) and gadopentetate dimeglumine (13.5 ± 8.9 cm3) (p = 0.98). The mean difference in Bland-Altman analysis for delayed-enhancement volume between the agents was 0.1 cm3. CONCLUSION. Qualitatively and quantitatively, delayed-enhancement MR images of ischemic myocardium obtained with 0.1 mmol/kg gadobenate dimeglumine are comparable to those obtained with 0.2 mmol/kg gadopentetate dimeglumine 5, 10, and 20 minutes after contrast administration.

Original languageEnglish (US)
Pages (from-to)533-539
Number of pages7
JournalAmerican Journal of Roentgenology
Volume205
Issue number3
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Gadolinium DTPA
Cross-Over Studies
Contrast Media
Image Enhancement
Myocardium
Gadolinium
gadobenic acid
Myocardial Infarction

Keywords

  • Cardiovascular MRI
  • Crossover studies
  • Delayed enhancement
  • Gadobenate dimeglumine
  • Gadolinium-based contrast agents
  • Gadopentetate dimeglumine
  • Myocardial scar
  • Randomized controlled trial

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Comparison of low-dose higher-relaxivity and standard-dose lower-relaxivity contrast media for delayed-enhancement mri : A blinded randomized crossover study. / Cheong, Benjamin Y.C.; Duran, Cihan; Preventza, Ourania A.; Muthupillai, Raja.

In: American Journal of Roentgenology, Vol. 205, No. 3, 01.09.2015, p. 533-539.

Research output: Contribution to journalArticle

@article{88f930d00c2c4588894d5c3722aac805,
title = "Comparison of low-dose higher-relaxivity and standard-dose lower-relaxivity contrast media for delayed-enhancement mri: A blinded randomized crossover study",
abstract = "OBJECTIVE. The gadolinium-based MRI contrast agent gadobenate dimeglumine has nearly twice the MR relaxivity of gadopentetate dimeglumine at 1.5 T. The purpose of this study was to determine whether a lower dose (0.1 mmol/kg) of gadobenate dimeglumine can be used to obtain delayed-enhancement MR images comparable to those obtained with a standard dose (0.2 mmol/kg) of gadopentetate dimeglumine. SUBJECTS AND METHODS. In this blinded randomized crossover study, 20 patients with known myocardial infarction underwent two separate delayed-enhancement MRI examinations after receiving 0.1 mmol/kg gadobenate dimeglumine and 0.2 mmol/kg gadopentetate dimeglumine (random administration). The conspicuity of lesion enhancement 5, 10, and 20 minutes after contrast administration was quantified as relative enhancement ratio (RER). RESULTS. With either gadolinium-based contrast agent, damaged myocardium had higher signal intensity than normal remote myocardium (RER > 4) on delayed-enhancement MR images, and the blood RER declined over time after contrast administration. The blood RER was not significantly higher for gadobenate dimeglumine than for gadopentetate dimeglumine at 5 and 10 minutes. Nevertheless, there was a larger reduction in blood RER for gadobenate dimeglumine than for gadopentetate dimeglumine between 5 and 10 minutes and between 10 and 20 minutes. The volumes of enhancement were similar for gadobenate dimeglumine (13.6 ± 8.8 cm3) and gadopentetate dimeglumine (13.5 ± 8.9 cm3) (p = 0.98). The mean difference in Bland-Altman analysis for delayed-enhancement volume between the agents was 0.1 cm3. CONCLUSION. Qualitatively and quantitatively, delayed-enhancement MR images of ischemic myocardium obtained with 0.1 mmol/kg gadobenate dimeglumine are comparable to those obtained with 0.2 mmol/kg gadopentetate dimeglumine 5, 10, and 20 minutes after contrast administration.",
keywords = "Cardiovascular MRI, Crossover studies, Delayed enhancement, Gadobenate dimeglumine, Gadolinium-based contrast agents, Gadopentetate dimeglumine, Myocardial scar, Randomized controlled trial",
author = "Cheong, {Benjamin Y.C.} and Cihan Duran and Preventza, {Ourania A.} and Raja Muthupillai",
year = "2015",
month = "9",
day = "1",
doi = "10.2214/AJR.14.13749",
language = "English (US)",
volume = "205",
pages = "533--539",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "3",

}

TY - JOUR

T1 - Comparison of low-dose higher-relaxivity and standard-dose lower-relaxivity contrast media for delayed-enhancement mri

T2 - A blinded randomized crossover study

AU - Cheong, Benjamin Y.C.

AU - Duran, Cihan

AU - Preventza, Ourania A.

AU - Muthupillai, Raja

PY - 2015/9/1

Y1 - 2015/9/1

N2 - OBJECTIVE. The gadolinium-based MRI contrast agent gadobenate dimeglumine has nearly twice the MR relaxivity of gadopentetate dimeglumine at 1.5 T. The purpose of this study was to determine whether a lower dose (0.1 mmol/kg) of gadobenate dimeglumine can be used to obtain delayed-enhancement MR images comparable to those obtained with a standard dose (0.2 mmol/kg) of gadopentetate dimeglumine. SUBJECTS AND METHODS. In this blinded randomized crossover study, 20 patients with known myocardial infarction underwent two separate delayed-enhancement MRI examinations after receiving 0.1 mmol/kg gadobenate dimeglumine and 0.2 mmol/kg gadopentetate dimeglumine (random administration). The conspicuity of lesion enhancement 5, 10, and 20 minutes after contrast administration was quantified as relative enhancement ratio (RER). RESULTS. With either gadolinium-based contrast agent, damaged myocardium had higher signal intensity than normal remote myocardium (RER > 4) on delayed-enhancement MR images, and the blood RER declined over time after contrast administration. The blood RER was not significantly higher for gadobenate dimeglumine than for gadopentetate dimeglumine at 5 and 10 minutes. Nevertheless, there was a larger reduction in blood RER for gadobenate dimeglumine than for gadopentetate dimeglumine between 5 and 10 minutes and between 10 and 20 minutes. The volumes of enhancement were similar for gadobenate dimeglumine (13.6 ± 8.8 cm3) and gadopentetate dimeglumine (13.5 ± 8.9 cm3) (p = 0.98). The mean difference in Bland-Altman analysis for delayed-enhancement volume between the agents was 0.1 cm3. CONCLUSION. Qualitatively and quantitatively, delayed-enhancement MR images of ischemic myocardium obtained with 0.1 mmol/kg gadobenate dimeglumine are comparable to those obtained with 0.2 mmol/kg gadopentetate dimeglumine 5, 10, and 20 minutes after contrast administration.

AB - OBJECTIVE. The gadolinium-based MRI contrast agent gadobenate dimeglumine has nearly twice the MR relaxivity of gadopentetate dimeglumine at 1.5 T. The purpose of this study was to determine whether a lower dose (0.1 mmol/kg) of gadobenate dimeglumine can be used to obtain delayed-enhancement MR images comparable to those obtained with a standard dose (0.2 mmol/kg) of gadopentetate dimeglumine. SUBJECTS AND METHODS. In this blinded randomized crossover study, 20 patients with known myocardial infarction underwent two separate delayed-enhancement MRI examinations after receiving 0.1 mmol/kg gadobenate dimeglumine and 0.2 mmol/kg gadopentetate dimeglumine (random administration). The conspicuity of lesion enhancement 5, 10, and 20 minutes after contrast administration was quantified as relative enhancement ratio (RER). RESULTS. With either gadolinium-based contrast agent, damaged myocardium had higher signal intensity than normal remote myocardium (RER > 4) on delayed-enhancement MR images, and the blood RER declined over time after contrast administration. The blood RER was not significantly higher for gadobenate dimeglumine than for gadopentetate dimeglumine at 5 and 10 minutes. Nevertheless, there was a larger reduction in blood RER for gadobenate dimeglumine than for gadopentetate dimeglumine between 5 and 10 minutes and between 10 and 20 minutes. The volumes of enhancement were similar for gadobenate dimeglumine (13.6 ± 8.8 cm3) and gadopentetate dimeglumine (13.5 ± 8.9 cm3) (p = 0.98). The mean difference in Bland-Altman analysis for delayed-enhancement volume between the agents was 0.1 cm3. CONCLUSION. Qualitatively and quantitatively, delayed-enhancement MR images of ischemic myocardium obtained with 0.1 mmol/kg gadobenate dimeglumine are comparable to those obtained with 0.2 mmol/kg gadopentetate dimeglumine 5, 10, and 20 minutes after contrast administration.

KW - Cardiovascular MRI

KW - Crossover studies

KW - Delayed enhancement

KW - Gadobenate dimeglumine

KW - Gadolinium-based contrast agents

KW - Gadopentetate dimeglumine

KW - Myocardial scar

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84942613086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942613086&partnerID=8YFLogxK

U2 - 10.2214/AJR.14.13749

DO - 10.2214/AJR.14.13749

M3 - Article

C2 - 26295638

AN - SCOPUS:84942613086

VL - 205

SP - 533

EP - 539

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 3

ER -